Objective To investigate the expression of HER-3 in TNBC tissues, and to explore the rela tionship and clinical value with liver metastasis. Methods TNBC tissue specimens and clinical data were collected, and the expression of HER-3 was detected by immunohistochemical and Western blot method. Clin-icopathological features and correlation with liver metastasis were analyzed, and the prognosis was analyzed by Kaplan Meier survival analysis. Results The positive rate of HER-3 in TNBC was 72.63% (69/95), and had correlation with TNM stage and lymph node status but not related to nuclear grade, p53 or tumor size. The incidence of liver metastasis in HER-3 positive group was significantly higher than the negative group sta-tistically. The median DFS of HER-3 negative and positive group were 18.4 and 14.5 months, and the median OS was 31.2 and 26.3 months with statistically significant. Conclusions The HER-3 expresses in TNBC, and promotes the invasion of cancer cells, and is closely related to liver metastasis, and can be used as a potential biomarker for assessing the prognosis of TNBC.%目的 探讨三阴性乳腺癌(TNBC)组织中表皮生长因子受体-3(HER-3)的表达情况,以及与肝转移的相关性和临床意义.方法 收集TNBC患者术后组织标本及临床资料,不同的表达水平的HER-3采用免疫组化法和蛋白质印迹法(Western blot)法检测,分析HER-3与临床病理特征及肝转移的相关性,其预后采用生存分析法(Kaplan-Meier)分析.结果 TNBC组织中HER-3的检测阳性率为72.63%(69/95),阳性表达与TNM分期及淋巴结转移相关,且肝转移发生率高于阴性组,差异有统计学意义(<0.05).TNBC组织中HER-3阴性与HER-3阳性组患者中位无病生存期(DFS)分别为18.4和14.5个月,中位总生存期(OS)分别为31.2和26.3个月,差异均有统计学意义.结论 HER-3在TNBC组织中过度表达,与淋巴结及肝脏转移相关,是不良预后的重要因素,可作为TNBC预后评估非常有潜力的生物学标志物.
展开▼
